HBK Investments’s Emergent Biosolutions EBS Stock Holding History

HBK Investments’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,285	Closed	-$610K	–	1131
2018 Q4	$610K	Buy	+10,285	New	+$663K	0.01%	840
2018 Q1	–	Sell	-12,300	Closed	-$572K	–	1010
2017 Q4	$572K	Buy	+12,300	New	+$518K	﹤0.01%	714
2016 Q3	–	Sell	-26,595	Closed	-$748K	–	864
2016 Q2	$748K	Buy	26,595 +551	+2%	+$21.6K	0.01%	639
2016 Q1	$947K	Buy	+26,044	New	+$920K	0.01%	604

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HBK Investments's EBS Position: Q1 2019 in Review

HBK Investments sold out of Emergent Biosolutions (EBS) in Q1 2019, closing a stake of 10,285 shares — an estimated $610K sold.

HBK Investments first reported a position in EBS in Q1 2016 and held it in 4 quarters. The position peaked at $947K in Q1 2016. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

HBK Investments reported no remaining Emergent Biosolutions position as of Q1 2019 after selling out during the quarter.
HBK Investments sold 10,285 Emergent Biosolutions shares in Q1 2019, an estimated $610K.
HBK Investments first reported a position in Emergent Biosolutions in Q1 2016 and held it in 4 quarters.
HBK Investments's Emergent Biosolutions position peaked at $947K in Q1 2016.
272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on HBK Investments's 13F filing for Q1 2019, filed 15 May 2019.